Literature DB >> 24992381

Liver transplantation for neuroendocrine tumour liver metastases.

Sheung Tat Fan1, Yves Patrice Le Treut, Vincenzo Mazzaferro, Andrew K Burroughs, Michael Olausson, Stefan Breitenstein, Andrea Frilling.   

Abstract

OBJECTIVE: Search and review of available literature were made to define the indications for and timing of liver transplantation for neuroendocrine tumour (NET) liver metastases.
METHODS: Electronic bibliographical databases were searched. Prospective and retrospective cohort studies and case-controlled studies were used for qualitative and quantitative synthesis of the systematic review. Reports of patients with liver transplantation alone for NET liver metastases of any origin or combined with resection of extrahepatic tumour deposits were recruited.
RESULTS: The number of patients who have undergone liver transplantation for NET liver metastases is 706. The post-transplant 5-year survival rate from the time of diagnosis was approximately 70%. NET patients with metastases confined to the liver and not poorly differentiated are favourable candidates for liver transplantation. Selection of patients based on evolution of tumours over 6 months is not recommended.
CONCLUSION: Non-resectable NET liver metastasis resistant to medical treatment and confined to the liver is an accepted indication for liver transplantation.
© 2014 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2014        PMID: 24992381      PMCID: PMC4266437          DOI: 10.1111/hpb.12308

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  19 in total

1.  Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients.

Authors:  Andrea Frilling; Massimo Malago; Frank Weber; Andreas Paul; Silvio Nadalin; Georgios C Sotiropoulos; Vito Cicinnati; Susanne Beckebaum; Andreas Bockisch; Jan Mueller-Brand; Michael Hofmann; Kurt W Schmid; Guido Gerken; Christoph E Broelsch
Journal:  Liver Transpl       Date:  2006-07       Impact factor: 5.799

2.  Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?

Authors:  Vincenzo Mazzaferro; Andrea Pulvirenti; Jorgelina Coppa
Journal:  J Hepatol       Date:  2007-07-26       Impact factor: 25.083

Review 3.  Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review.

Authors:  Eliano Bonaccorsi-Riani; Carlos Apestegui; Anne Jouret-Mourin; Christine Sempoux; Pierre Goffette; Olga Ciccarelli; Ivan Borbath; Catherine Hubert; Jean François Gigot; Ziad Hassoun; Jan Lerut
Journal:  Transpl Int       Date:  2010-05-05       Impact factor: 3.782

4.  Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors.

Authors:  Jens Rosenau; Matthias J Bahr; Reinhard von Wasielewski; Michael Mengel; Hartmut H J Schmidt; Björn Nashan; Hauke Lang; Jürgen Klempnauer; Michael P Manns; Klaus H W Boeker
Journal:  Transplantation       Date:  2002-02-15       Impact factor: 4.939

5.  Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes.

Authors:  Patrizia Burra; Giacomo Germani; Renè Adam; Vincent Karam; Alfredo Marzano; Pietro Lampertico; Mauro Salizzoni; Franco Filipponi; Jurgen L Klempnauer; Denis Castaing; Murat Kilic; Luciano De Carlis; Peter Neuhaus; Sezai Yilmaz; Andreas Paul; Antonio D Pinna; Andrew K Burroughs; Francesco P Russo
Journal:  J Hepatol       Date:  2012-10-23       Impact factor: 25.083

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival.

Authors:  Frederike G I van Vilsteren; Edwina S Baskin-Bey; David M Nagorney; Schuyler O Sanderson; Walter K Kremers; Charles B Rosen; Gregory J Gores; Timothy J Hobday
Journal:  Liver Transpl       Date:  2006-03       Impact factor: 5.799

8.  Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report.

Authors:  Y P Le Treut; E Grégoire; J Belghiti; O Boillot; O Soubrane; G Mantion; D Cherqui; D Castaing; P Ruszniewski; P Wolf; F Paye; E Salame; F Muscari; F R Pruvot; J Baulieux
Journal:  Am J Transplant       Date:  2008-04-29       Impact factor: 8.086

9.  Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease.

Authors:  A Frilling; J Li; E Malamutmann; K-W Schmid; A Bockisch; C E Broelsch
Journal:  Br J Surg       Date:  2009-02       Impact factor: 6.939

10.  Neuroendocrine Liver Metastases and Orthotopic Liver Transplantation: The US Experience.

Authors:  N Thao T Nguyen; Theresa R Harring; John A Goss; Christine A O'Mahony
Journal:  Int J Hepatol       Date:  2011-12-29
View more
  20 in total

Review 1.  Surgical management of neuroendocrine tumor-associated liver metastases: a review.

Authors:  Miu Yee Chan; Ka Wing Ma; Albert Chan
Journal:  Gland Surg       Date:  2018-02

Review 2.  Liver transplantation for unresectable pancreatic neuroendocrine tumors with liver metastases in an era of transplant oncology.

Authors:  Keita Shimata; Yasuhiko Sugawara; Taizo Hibi
Journal:  Gland Surg       Date:  2018-02

Review 3.  The Landmark Series: Neuroendocrine Tumor Liver Metastases.

Authors:  Alexandra Gangi; James R Howe
Journal:  Ann Surg Oncol       Date:  2020-07-06       Impact factor: 5.344

4.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

Review 5.  Carcinoid Syndrome: Updates and Review of Current Therapy.

Authors:  Kira Oleinikov; Shani Avniel-Polak; David J Gross; Simona Grozinsky-Glasberg
Journal:  Curr Treat Options Oncol       Date:  2019-07-09

Review 6.  [Oligometastases of neuroendocrine tumors-extent of surgery].

Authors:  F Bösch; J Werner; M K Angele; M O Guba
Journal:  Chirurg       Date:  2018-07       Impact factor: 0.955

Review 7.  The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons.

Authors:  Carlo Sposito; Michele Droz Dit Busset; Davide Citterio; Marco Bongini; Vincenzo Mazzaferro
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

8.  Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET.

Authors:  Chengjun Sui; Feng Xu; Weifeng Shen; Li Geng; Feng Xie; Binghua Dai; Jiongjiong Lu; Minfeng Zhang; Jiamei Yang
Journal:  Tumour Biol       Date:  2014-11-06

Review 9.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

Review 10.  Refractory carcinoid syndrome: a review of treatment options.

Authors:  Rachel P Riechelmann; Allan A Pereira; Juliana F M Rego; Frederico P Costa
Journal:  Ther Adv Med Oncol       Date:  2016-11-02       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.